Navidea Biopharmaceuticals Announces Completion of Additional Fundamental Clinical Trial for Radiopharmaceutical Agent, NAV4694, in Alzheimer’s Disease

Navidea Biopharmaceuticals, a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced the completion of a study of its novel radiopharmaceutical NAV4694 as a biomarker for visual detection and quantification of cerebral β-amyloid in diagnosing Alzheimer’s disease (AD).
Yahoo! Medical News